Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients

Covic, Adrian; Schelling, Jeffrey R.; Constantiner, Marigel; Iyengar, Sudha K.; Sedor, John R.

doi:10.1046/j.1523-1755.2000.00335.x

Cited by 55 publications

(38 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anti-glutamic acid decarboxylase may be used at diabetes onset; however, it has yet to be validated as a reliable diagnosis tool several years after the diabetes onset, as is the case when ESRD diabetics are listed for a SPK transplant. C-peptide level as an isolated parameter is unreliable for diabetes diagnosis in ESRD patients (33,34). Others limitations to the study are that criteria for pancreas allograft failure are poorly described in UNOS.…”

Section: Discussionmentioning

confidence: 94%

Outcomes of Simultaneous Pancreas-Kidney Transplantation in Type 2 Diabetic Recipients

Sampaio

Kuo

Bunnapradist

2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives Type 2 diabetic patients with end-stage renal disease may receive a simultaneous pancreas-kidney (SPK) transplant. However, outcomes are not well described. Risks for death and graft failure were examined in SPK type 2 diabetic recipients.Design, setting, participants, & measurements Using the United Network for Organ Sharing database, outcomes of SPK transplants were compared between type 2 and type 1 diabetic recipients. All primary SPK adult recipients transplanted between 2000 and 2007 (n ϭ 6756) were stratified according to end-stage pancreas disease diagnosis (type 1: nϭ6141, type 2: nϭ582). Posttransplant complications and risks for death and kidney/pancreas graft failure were compared. ResultsOf the 6756 SPK transplants, 8.6% were performed in recipients with a type 2 diabetes diagnosis. Rates of delayed kidney graft function and primary kidney nonfunction were higher in the type 2 diabetics. Five-year overall and death-censored kidney graft survival were inferior in type 2 diabetics. After adjustment for other risk factors, including recipient (age, race, body weight, dialysis time, and cardiovascular comorbidities), donor, and transplant immune characteristics, type 2 diabetes was not associated with increased risk for death or kidney or pancreas failure when compared with type 1 diabetic recipients. ConclusionsAfter adjustment for other risk factors, SPK recipients with type 2 diabetes diagnosis were not at increased risk for death, kidney failure, or pancreas failure when compared with recipients with type 1 diabetes.

show abstract

Section: Discussionmentioning

confidence: 94%

Outcomes of Simultaneous Pancreas-Kidney Transplantation in Type 2 Diabetic Recipients

Sampaio

Kuo

Bunnapradist

2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…C-peptide is primarily catabolized by the kidney, thus rendering its use as sole diagnostic marker perhaps flawed in patients with ESRD [19]. Nath et al analyzed all pancreas transplants performed at their institution over an eight-year period, using clinical criteria to distinguish between T1DM and T2DM recipients [20].…”

Section: Pancreas Transplantation For Type 2 Diabetes Mellitusmentioning

confidence: 99%

Pancreas Transplantation of Non-Traditional Recipients

Sayed

Turgeon

2014

Curr Transpl Rep

View full text Add to dashboard Cite

Solid organ pancreas transplantation is a durable treatment for establishing normal blood glucose levels in patients with diabetes. Historically, younger patients with type 1 diabetes have been the primary recipients of pancreas transplants. As surgical techniques and post-operative immunosuppression regimens have continued to improve, indications have expanded such that non-traditional recipients are being evaluated for pancreas transplantation. These recipients include patients with type 2 diabetes, patients older than 50 years of age, and patients with chronic infectious diseases, including HIV and HCV. Despite limited literature in these patient populations, pancreas transplantation is a viable treatment for endocrine pancreas failure in appropriately selected patients, regardless of disease etiology or age. This review summarizes the current literature on pancreas transplantation in non-traditional recipients.

show abstract

“…Between (8), immunosuppressive diseases, or using immunosuppressive drugs were excluded. Individuals that had stopped insulin therapy for more than two weeks since the diagnosis of diabetes and had not developed DKA were also excluded.…”

Section: Subjectsmentioning

confidence: 99%

Relationship between the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients

Rodacki¹,

Zajdenverg

Albernaz

et al. 2004

Braz J Med Biol Res

View full text Add to dashboard Cite

The objective of the present study was to determine whether the duration of disease has any influence on the prevalence of glutamic acid decarboxylase autoantibodies (GADA) in Brazilian patients with type 1 diabetes (T1D) and variable disease duration. We evaluated 83 patients with T1D. All participants were interviewed and blood was obtained for GADA measurement by a commercial radioimmunoassay (RSR Limited, Cardiff, UK). Four groups of patients were established according to disease duration: A) 1-5 years of disease (N = 24), B) 6-10 years of disease (N = 19), C) 11-15 years of disease (N = 25), and D) >15 years of disease (N = 15). GADA prevalence and its titers were determined in each group. GADA was positive in 38 patients (45.8%) and its frequency did not differ between the groups. The prevalence was 11/24 (45.8%), 8/19 (42.1%), 13/25 (52%), and 6/15 (40%) in groups A, B, C, and D, respectively (P = 0.874). Mean GADA titer was 12.54 ± 11.33 U/ml for the sample as a whole and 11. 95 ± 11.8, 12.85 ± 12.07, 10.57 ± 8.35, and 17.45 ± 16.1 U/ml for groups A, B, C, and D, respectively (P = 0.686). Sex, age at diagnosis or ethnic background had no significant effect on GADA (+) frequency. In conclusion, in this transversal study, duration of disease did not affect significantly the prevalence of GADA or its titers in patients with T1D after one year of diagnosis. This was the first study to report this finding in the Brazilian population.

show abstract

Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients

Cited by 55 publications

References 41 publications

Outcomes of Simultaneous Pancreas-Kidney Transplantation in Type 2 Diabetic Recipients

Outcomes of Simultaneous Pancreas-Kidney Transplantation in Type 2 Diabetic Recipients

Pancreas Transplantation of Non-Traditional Recipients

Relationship between the prevalence of anti-glutamic acid decarboxylase autoantibodies and duration of type 1 diabetes mellitus in Brazilian patients

Contact Info

Product

Resources

About